Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock?

Hims & Hers shares crater as Novo Nordisk files a lawsuit against the telehealth firm. BofA analysts see significant further downside in HIMS stock.

Barchart · Feb 10

Trump Rx prescription drug site ‘not a solution’ for many patients, experts say

New website lists only limited number of medications – and many of them cost less in generic form elsewhere

The Guardian - US · Feb 10

Super Bowl ads try to overcome tough times with health, caring and the usual laughs

At a difficult time for America, Super Bowl advertisers are asking viewers to take care of themselves and others — and maybe even crack a smile

The Independent UK · Feb 8

From analysis to the latest developments in health,
read the most diverse news in one place.

Hims & Hers drops plan for knockoff of Novo Nordisk's new Wegovy weight loss pill

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug

The Independent UK · Feb 7

Experts warn against ‘worrying’ rise in dangerous weight-loss ‘jab hacks’

Almost half of the 1.6 million people using weight-loss jabs admit to either trying dosing ‘hacks’, or turning to unlicensed drugs and sellers

The Independent UK · Feb 7

Trump and Dr. Oz bring ‘As Seen on TV’ vibes to Rx coupon portal for cheap ‘fat drugs’

ANALYSIS: The president’s latest gambit at health care affordability, TrumpRx, isn’t the panacea he promised for access to low-cost GLP-1 drugs like Wegovy, Ozempic and Mounjaro— but some experts tell Andrew Feinberg that the effort should not be dismissed

The Independent UK · Feb 6

US health company launches weight-loss pill that Novo Nordisk calls an 'untested knockoff'

The American telehealth company announced the launch of a compounded weight-loss pill for €41, drawing criticism from Novo Nordisk, the Danish company behind the weight-loss drug Wegovy, which called the product an “untested knockoff.”

Euronews · Feb 6

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk's APAC Supply Chain Guru: How Muhammad Shahid's AI-Powered Forecasting Cut Planning Cycles by 25% and Supercharged Pharma Delivery

Today’s pharmaceutical supply chains are under constant pressure. Evolving demands, complex regulations, and razor-thin margins mean one wrong forecast can ripple into shortages across entire regions.

inkl · Feb 6

TrumpRx is live. Here's what the website shows

The site is a key part of President Trump's efforts to lower health costs but isn't expected to significantly affect drug prices.

Axios · Feb 6

Hims & Hers launches copy of Wegovy pill, prompting legal threats from drugmaker Novo Nordisk

Telehealth company Hims & Hers is launching a cheaper, off-brand version of the blockbuster weight loss pill Wegovy

The Independent UK · Feb 5

The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles

Eli Lilly surges past the trillion-dollar mark as aggressive manufacturing expansion drives volume growth that eclipses rival Novo Nordisk in 2026.

MarketBeat · Feb 5

New weight loss drug by Pfizer shows promising results in trial

Pfizer acquired the drug’s developer following a bidding war with Novo Nordisk last year

The Independent UK · Feb 4

Novo Nordisk shares plunge on outlook warning as Mounjaro rival races ahead

Wegovy and Ozempic maker Novo Nordisk forecast plunging sales and earnings in 2026, which saw the Danish drugmaker’s shares plummet by nearly a fifth.

Evening Standard · Feb 4

Novo Nordisk stock sinks by 17% after bleak 2026 forecast

Shares tumbled after the company predicted a 5–13% decline in 2026 sales and operating profit, citing lower US prices and rising competition.

Euronews · Feb 4

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK · Feb 4

Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition

Barchart · Feb 3

As Novo Nordisk Stock Breaks Below Key Support Levels, Should You Buy the Dip?

Novo Nordisk stock sank as management forecasts decelerating growth in 2026. But should you treat this selloff in NVO shares as a buying opportunity? Let’s find out.

Euronews · Feb 2

Why Denmark can't use Ozempic as a trump card with the US in Greenland talks

Novo Nordisk, the Danish manufacturer of weight-loss drugs Ozempic and Wegovy, has a large market share in the US. But it's not enough to put pressure on US President Donald Trump's administration during Greenland talks, experts say.

Barchart · Feb 1

Commodity Volatility, Earnings and Other Key Things to Watch

Markets enter February following a volatile final trading day of January that saw investors grappling with hotter-than-expected inflation data alongside news of a new Federal Reserve chair nominee.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK · Jan 29

Small risk of severe acute pancreatitis with weight-loss jabs, UK regulator warns

Agency updates guidance after increase in reports of condition to its yellow card scheme

The Independent UK · Jan 28

Eye-stroke, vomiting and burst colon: Lawsuits accuse weight-loss drugs of severe side effects

Thousands of patients have filed lawsuits against drug producers claiming side effects - but the companies insist their products are properly tested

The Independent UK · Jan 28

Layoffs are piling up, heightening worker anxiety. Here are some of the biggest job cuts recently

As layoffs pile up, workers are feeling increasingly anxious about the job market

GOBankingRates · Jan 25

5 Stocks To Keep an Eye On in 2026, According to Experts

Healthcare, retail and finance stocks could do well in 2026. See five picks that experts say could have major upside potential. Find out more right now.

The Guardian - UK · Jan 24

Fake weight-loss medication in tablet form could flood Britain, experts warn

Better regulation and enforcement urged before launch of oral treatments, which criminals are likely to try to exploit

Barchart · Jan 21

The New Wegovy Pill Is Already Popular. Does That Make Novo Nordisk Stock a Buy for Q1?

Novo Nordisk entered 2026 with fresh momentum after the U.S. launch of its oral Wegovy pill. Is the stock a buy now?

MarketBeat · Jan 19

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

1 … 5 6 7 8

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.